Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest colitis Stories

2011-01-12 11:34:00

In the news release, Team Challenge Endurance Training Program Generates $8 Million for Crohn's & Colitis Foundation in 2010, issued 11-Jan-2011 by Crohn's & Colitis Foundation over PR Newswire, we are advised by the company that the third paragraph, first sentence, should read "...Roberto Martinez from The Bachelorette" rather than "...Fernando Martinez from The Bachelorette" as originally issued inadvertently. The complete, corrected release follows: Team Challenge Endurance...

2011-01-11 14:44:00

NEW YORK, Jan. 11, 2011 /PRNewswire/ -- In 2010, over 2,000 people ran, walked, or cycled with the Crohn's & Colitis Foundation's endurance training and fundraising program, Team Challenge. These participants at all fitness levels raised $8 million for research, education, and support services for patients suffering from Crohn's disease and ulcerative colitis, chronic and often debilitating digestive diseases affecting over 1.4 million Americans. To view the multimedia assets...

2011-01-10 05:18:00

UPPER SADDLE RIVER, N.J., Jan. 10, 2011 /PRNewswire/ -- WellApps, LLC, developer of GI Monitor for Crohn's and Ulcerative Colitis, announced today the release of Colonoscopy Prep Assistant. During the portion of colonoscopy preparation when a patient ingests a liquid laxative, Colonoscopy Prep Assistant tracks the number of glasses completed and time between glasses, notifying the patient when it's time to drink their next glass. The app is available for free in iTunes and the Android...

2011-01-06 07:00:00

OKLAHOMA CITY, Jan. 6, 2011 /PRNewswire/ -- Altheus Therapeutics, Inc., announced that it has completed a two dose, double-blind, active-controlled Phase I clinical trial of the safety and tolerability of Zoenasa(TM) Rectal Suspension in adult patients with left-sided, or distal, ulcerative colitis. No serious adverse events were experienced by patients in this study. "We are excited to have achieved this milestone, as it prepares Altheus to begin our planned Phase II clinical program to...

2011-01-05 09:15:00

WAYLAND, Mass., Jan. 5, 2011 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotech company developing an innovative platform technology to deliver orally-active antibodies to the gastrointestinal tract, announced today that it has generated compelling pre-clinical data in animal models of inflammatory bowel disease (IBD). Avaxia's orally administered anti-TNF product AVX-470 significantly reduced disease severity in three different animal models and showed superior efficacy to...

2010-12-29 07:00:00

HORSHAM, Pa., Dec. 29, 2010 /PRNewswire/ -- Centocor Ortho Biotech Inc. announced today that it has filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) requesting the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy. REMICADE was designated orphan drug status by the FDA on...

2010-12-21 08:00:00

ALBUQUERQUE, N.M., Dec. 21, 2010 /PRNewswire/ -- Exagen Diagnostics, Inc., a specialty diagnostics laboratory that discovers, develops and markets proprietary tests, today announced that it has been awarded $400,000 in funding under the IRS Qualifying Therapeutic Discovery Project (QTDP) program, which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010. Proceeds from the grants will be used to advance the development of biomarker studies underway,...

2010-12-14 23:58:45

Scientists at the University of California, San Diego School of Medicine have described for the first time a key inhibitory role for the IL-1 signaling pathway in the human innate immune system, providing novel insights into human inflammatory bowel disease (IBD) and potential new treatments. The research, led by Jose M. Gonzalez-Navajas, PhD, and Eyal Raz, MD, a professor of medicine at UC San Diego, is published as a Brief Definitive Report in the December issue of The Journal of...

2010-12-14 00:01:27

The Crohn's & Colitis Foundation was proud to honor three leaders in the field of IBD research and treatment on Friday, December 10th at its 2010 Advances in Inflammatory Bowel Diseases Clinical & Research Conference (http://www.AdvancesInIBD.com) in Hollywood, Florida. New York, NY (Vocus) December 13, 2010 The Crohn's & Colitis Foundation was proud to honor three leaders in the field of IBD research and treatment on Friday, December 10th at its 2010 Advances in Inflammatory...

2010-12-10 00:00:38

Not Easily Identifiable, Many People Suffering from IBS Simply Don't Know Beltsville, MD (Vocus) December 8, 2010 In today's world of quick fixes and fad diets, successfully treating a chronic condition has become significantly more difficult. Irritable Bowel Syndrome affects between 15 and 20 percent of all adults in the Western world. However, IBS is difficult to identify due to the numerous symptoms associated with it. Almost 40 percent of IBS sufferers report symptoms severe and...


Latest colitis Reference Libraries

0_9f897835bb09adc2a84fda23893d87f8
2011-04-15 13:50:01

Clostridium difficile, also known as "CDF/cdf", or "C. diff", is a Gram-positive bacteria of the genus Clostridium that causes severe diarrhea and other intestinal disease when competing bacteria in the gut flora are wiped out by antibiotics. They are anaerobic, spore-forming rods and is the most serious cause of antibiotic-associated diarrhea and potentially to pseudomembranous colitis. C. difficile bacteria naturally resides in the gut of a small percentage of the adult population. Others...

More Articles (1 articles) »